• Molecular NameMometasone
  • SynonymNA
  • Weight521.437
  • Drugbank_IDDB00764
  • ACS_NO105102-22-5
  • Show 3D model
  • LogP (experiment)3.9
  • LogP (predicted, AB/LogP v2.0)3.91
  • pkaN/A
  • LogD (pH=7, predicted)3.91
  • Solubility (experiment)Insoluble
  • LogS (predicted, ACD/Labs)(ph=7)-5.74
  • LogSw (predicted, AB/LogsW2.0)0.0
  • Sw (mg/ml) (predicted, ACD/Labs)0.0
  • No.of HBond Donors1
  • No.of HBond Acceptors6
  • No.of Rotatable Bonds5
  • TPSA93.81
  • StatusFDA approved
  • AdministrationTopical, nasal
  • PharmacologyA glucocorticoid steroid used topically to reduce inflammation of the skin or in the airways.
  • Absorption_valueN/A
  • Absorption (description)Nasal spray is virtually undetectable in plasma
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein binding98.5
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmHepatic. Extensive metabolism to multiple metabolites.
  • Half life5.8 h
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityThe potential for acute toxic effects following overdose with the mometasone inhaler is low. However, habitual overuse of the product can cause symptoms of steroid overload, including menstrual irregularities, acne, obesity, and muscle weakness. Single oral doses up to 8000 μg have been studied on human volunteers with no adverse events reported.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A